| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 24th February 2021 | Michael J Brown | 2,249 | Payment by withholding | $156.27 | $351,451.23 |
| 24th February 2021 | Michael J Brown | 7,236 | Grant/award etc. | $0.00 | |
| 1st January 2021 | Chandler Robinson | 2,327 | Payment by withholding | $6.12 | $14,241.24 |
| 1st January 2021 | Chandler Robinson | 6,724 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Kim R Tsuchimoto | 1,231 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Andrew Paul Mazar | 1,937 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Kim R Tsuchimoto | 504 | Payment by withholding | $6.12 | $3,084.48 |
| 1st January 2021 | Andrew Paul Mazar | 671 | Payment by withholding | $6.12 | $4,106.52 |
| 31st December 2020 | Michael J Brown | 322 | Exercise of derivative | $0.00 | |
| 31st December 2020 | Arthur J Klausner | 322 | Exercise of derivative | $0.00 |
Monopar Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014.
Ticker: MNPR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1645469
Employees: 7
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Monopar携手经验丰富的Medtech高管，探寻将MNPR-101用作uPAR癌症手术显像剂的潜力
2nd March 2021
Monopar Therapeutics to Present at Upcoming Investor Conferences
24th February 2021